Cargando…
Phenelzine treatment increases transcription factor AP-2 levels in rat brain
BACKGROUND: The elevations of noradrenaline (NA) and serotonin (5-HT) levels in response to acute serotonin reuptake inhibitor (SSRI) or tricyclic antidepressant (TCA) exposure are not consistent with the time course for the therapeutic action of these antidepressants. Thus, neuronal adaptations are...
Autores principales: | , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC194722/ https://www.ncbi.nlm.nih.gov/pubmed/12943557 http://dx.doi.org/10.1186/1471-2210-3-10 |
_version_ | 1782120930116370432 |
---|---|
author | Damberg, Mattias Berggård, Cecilia Oreland, Lars |
author_facet | Damberg, Mattias Berggård, Cecilia Oreland, Lars |
author_sort | Damberg, Mattias |
collection | PubMed |
description | BACKGROUND: The elevations of noradrenaline (NA) and serotonin (5-HT) levels in response to acute serotonin reuptake inhibitor (SSRI) or tricyclic antidepressant (TCA) exposure are not consistent with the time course for the therapeutic action of these antidepressants. Thus, neuronal adaptations are needed for the therapeutic effect to arise. Transcription factor Activating Protein –2 (AP-2) is critical for mammalian neural gene expression. Several genes involved in brainstem CNS transmitter systems, especially the monoamines, have AP-2 binding sites in their regulatory regions. We have previously shown that treatment with citalopram and imipramin resulted in a decrease in AP-2α and AP-2β levels in rat brain. We have also reported an association between a specific genotype of AP-2β to personality traits, binge-eating disorder and platelet monoamine oxidase (MAO) activity. RESULTS: Subchronic administration (10 days) of phenelzine (PLZ) increased the levels of AP-2α, AP-2β and the DNA binding activity of AP-2 in nuclear extracts prepared from rat whole brain when compared with sham treated animals. CONCLUSION: These data suggest that AP-2 is not involved in the theraputic effect of antidepressants. Rather, the effects of antidepressants seen on the levels of AP-2 might be involved in the expression of side-effects during the lag-period. |
format | Text |
id | pubmed-194722 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2003 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-1947222003-09-16 Phenelzine treatment increases transcription factor AP-2 levels in rat brain Damberg, Mattias Berggård, Cecilia Oreland, Lars BMC Pharmacol Research Article BACKGROUND: The elevations of noradrenaline (NA) and serotonin (5-HT) levels in response to acute serotonin reuptake inhibitor (SSRI) or tricyclic antidepressant (TCA) exposure are not consistent with the time course for the therapeutic action of these antidepressants. Thus, neuronal adaptations are needed for the therapeutic effect to arise. Transcription factor Activating Protein –2 (AP-2) is critical for mammalian neural gene expression. Several genes involved in brainstem CNS transmitter systems, especially the monoamines, have AP-2 binding sites in their regulatory regions. We have previously shown that treatment with citalopram and imipramin resulted in a decrease in AP-2α and AP-2β levels in rat brain. We have also reported an association between a specific genotype of AP-2β to personality traits, binge-eating disorder and platelet monoamine oxidase (MAO) activity. RESULTS: Subchronic administration (10 days) of phenelzine (PLZ) increased the levels of AP-2α, AP-2β and the DNA binding activity of AP-2 in nuclear extracts prepared from rat whole brain when compared with sham treated animals. CONCLUSION: These data suggest that AP-2 is not involved in the theraputic effect of antidepressants. Rather, the effects of antidepressants seen on the levels of AP-2 might be involved in the expression of side-effects during the lag-period. BioMed Central 2003-08-28 /pmc/articles/PMC194722/ /pubmed/12943557 http://dx.doi.org/10.1186/1471-2210-3-10 Text en Copyright © 2003 Damberg et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL. |
spellingShingle | Research Article Damberg, Mattias Berggård, Cecilia Oreland, Lars Phenelzine treatment increases transcription factor AP-2 levels in rat brain |
title | Phenelzine treatment increases transcription factor AP-2 levels in rat brain |
title_full | Phenelzine treatment increases transcription factor AP-2 levels in rat brain |
title_fullStr | Phenelzine treatment increases transcription factor AP-2 levels in rat brain |
title_full_unstemmed | Phenelzine treatment increases transcription factor AP-2 levels in rat brain |
title_short | Phenelzine treatment increases transcription factor AP-2 levels in rat brain |
title_sort | phenelzine treatment increases transcription factor ap-2 levels in rat brain |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC194722/ https://www.ncbi.nlm.nih.gov/pubmed/12943557 http://dx.doi.org/10.1186/1471-2210-3-10 |
work_keys_str_mv | AT dambergmattias phenelzinetreatmentincreasestranscriptionfactorap2levelsinratbrain AT berggardcecilia phenelzinetreatmentincreasestranscriptionfactorap2levelsinratbrain AT orelandlars phenelzinetreatmentincreasestranscriptionfactorap2levelsinratbrain |